AMVUTTRA
@amvuttra.com
Learn about AMVUTTRA® (vutrisiran), an Rx medicine for adults with ATTR-CM and hATTR-PN. See safety info on low vitamin A levels and PI.
AMVUTTRA's Company Logos
AMVUTTRA's Brand Colors
Hex Code
Color name
RGB
HSL
CMYK
#E7004C
Red Ribbon
231, 0, 76
340, 100, 45
0, 100, 67, 9
#F87564
Bittersweet
248, 117, 100
7, 91, 68
0, 53, 60, 3
#000000
Black
0, 0, 0
0, 0, 0
0, 0, 0, 100
About AMVUTTRA
AMVUTTRA® (vutrisiran) is a specialized prescription medication developed by Alnylam Pharmaceuticals, aimed at treating polyneuropathy caused by hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in adults. Delivered through an injection every three months by a healthcare professional, AMVUTTRA is the first of its kind designed to provide significant improvements in nerve function and quality of life for patients facing this challenging condition.
The effectiveness of AMVUTTRA has been validated through various assessments, including the Norfolk Quality of Life-Diabetic Neuropathy (QoL-DN) questionnaire and the mNIS+7 scale, measuring nerve strength and sensation. While it offers hope to over 1,300 patients in the U.S. alone, users should be aware of potential side effects, such as low vitamin A levels and joint pain, necessitating regular consultations with healthcare providers. Alnylam Pharmaceuticals also emphasizes support through their Alnylam Assist program, ensuring patients receive comprehensive information and guidance throughout their treatment journey.
Brand industry
Health
Company type
Suggest company type
Year founded
Suggest founded year
Company size
Suggest company size
Related Brands
Tags
TTR silencer
ATTR cardiomyopathy medicine
HATTR polyneuropathy medicine
Prescription drug for rare amyloidosis
